FBIO vs. BOLT, MTEM, SPRB, BCTX, NRXP, ACXP, APRE, APLM, DARE, and IPA
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Spruce Biosciences (SPRB), BriaCell Therapeutics (BCTX), NRx Pharmaceuticals (NRXP), Acurx Pharmaceuticals (ACXP), Aprea Therapeutics (APRE), Apollomics (APLM), Daré Bioscience (DARE), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "pharmaceutical preparations" industry.
Fortress Biotech (NASDAQ:FBIO) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
Fortress Biotech has a net margin of -69.13% compared to Bolt Biotherapeutics' net margin of -556.59%. Bolt Biotherapeutics' return on equity of -51.74% beat Fortress Biotech's return on equity.
96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 33.4% of Fortress Biotech shares are held by insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Fortress Biotech received 244 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 65.57% of users gave Bolt Biotherapeutics an outperform vote while only 64.80% of users gave Fortress Biotech an outperform vote.
Fortress Biotech has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Fortress Biotech has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
In the previous week, Bolt Biotherapeutics had 11 more articles in the media than Fortress Biotech. MarketBeat recorded 25 mentions for Bolt Biotherapeutics and 14 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.46 beat Bolt Biotherapeutics' score of 0.13 indicating that Fortress Biotech is being referred to more favorably in the media.
Fortress Biotech presently has a consensus price target of $30.00, suggesting a potential upside of 1,454.40%. Bolt Biotherapeutics has a consensus price target of $3.50, suggesting a potential upside of 341.42%. Given Fortress Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Bolt Biotherapeutics.
Summary
Fortress Biotech beats Bolt Biotherapeutics on 13 of the 18 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
